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Abstract. The similarity factor, f2, measures the sameness of dissolution proﬁles. The following
commentary is an overview of discussions and presentations from a group of industry and US regulatory
experts that have integrated the science and regulatory research and practice for assessing product
performance, particularly for modiﬁed-release (MR) dosage forms, using f2. For a drug development
sponsor or applicant with an orally complex dosage formulation, it is critical to understand dissolution
methods and the similarity factor and how and/or when to apply it in their NDA, ANDA, or PMA
submission. As part of any regulatory submission, it is critical to justify that the product performance has
not been impacted by any change in the manufacturing process and/or the delayed and/or prolonged drug
release characteristics compared to a similar conventional or another orally complex dosage form. The
purposes of this document are (1) to provide a description of appropriate dissolution methods, how is the
f2 calculated and how it can be used to justify product performance similarity, or not; (2) to provide an
overview of alternative methods available for dissolution proﬁle comparisons, and (3) to illustrate how
applying these concepts in a focused way supports approval of submissions and regulatory dossiers and
aligns them with on-going science and regulatory initiatives. A case study will be used as an example to
demonstrate how dissolution testing and the f2 calculation results can impact regulatory outcomes from
an NDA (505(b)(1)), NDA (505(b)(2)), ANDA (505(j)), supplemental NDAs/ANDAs, or PMA
perspective.
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BACKGROUND INFORMATION
The authors of this paper were selected to present a
roundtable presentation entitled, BScientiﬁc and Regulatory
Standards for Assessing Product Performance Using the
Similarity Factor, f2^ at 2013 American Association of Pharma-
ceutical Scientists (AAPS) Annual Meeting and Exposition
which took place November 10–14, 2013 in San Antonio, Texas.
The moderators of the roundtable were Lynn Gold, PhD and
Loan Pham, PhD. Vivian Gray presented the topic, BScientiﬁc
Considerations Using the Similarity Factor, f2^. Ruth Stevens,
PhD, MBA presented the topic, BPractical Applications of the
Similarity Factor, f2^, followed byAngelicaDorantes, PhD,who
presented BRegulatory Applications of f2^. The authors were
invited by the Scientiﬁc Journal of the AAPS to submit their
combined presentations as a commentary to this journal for
wider distribution among its community.
There is a growing recognition of the importance of
submitting a quality regulatory submission, especially when
FDA re fu se s to ﬁ l e an app l i ca t ion under 21
CFR314.101(d)(3) because the application or abbreviated
application is incomplete (does not on its face contain
information required under section 505(b) and 21 CFR
314.50). This is what happened to Merck & Co when they
ﬁrst submitted their NDA, ezetimibe/atorvastatin tablets.
Pertinent to this commentary, two out of the four reasons
quoted for the ﬁling deﬁciency were as follows: (1) BThe
primary stability batches were manufactured at a Research
and Development (R&D) facility. Provide stability data to
bridge the R&D manufacturing to the commercial
manufacturing (i.e., data for three commercial batches with
at least three months of long term and accelerated data) as
well as multipoint dissolution proﬁles.^ and (2) BThe applica-
tion did not include any information to bridge the perfor-
mance of the clinically tested batches to the commercial
products (e.g., multipoint in vitro dissolution proﬁles)^ (1).
This paper will discuss further how the similarity f2
statistical comparison was used for the reformulated Asacol®
capsule product, not as a point estimator but in combination
with a statistical model independent multivariate conﬁdence
region procedure (Bootstrap approach), where wide variabil-
ity was observed in the dissolution proﬁles. It will also brieﬂy
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discuss alternative statistical approaches that may be consid-
ered when application of the f 2 metric is not appropriate.
SCIENTIFIC CONSIDERATIONS USING THE SIMI
LARITY FACTOR, F2
Information on f2 can be found in at least three guidances:
Guidance for Industry, Dissolution Testing of Immediate Release
SolidOralDosage Forms (2),Guidance for Industry,Waiver of In
Vivo Bioavailability and Bioequivalence Studies for Immediate
Release Solid Oral Dosage Forms Based on the a
Biopharmaceutics Classiﬁcation System (3), and Guidance for
Industry Immediate Release Solid Oral Dosage Forms, Scale-Up
and Post-Approval Changes: Chemistry, Manufacturing Con-
trols, In Vitro Dissolution Testing and In Vivo Bioequivalence
Documentation (4). These three guidances have essentially the
same information but the most extensive treatment of the subject
is from the Guidance for Industry, Dissolution Testing of
Immediate Release Solid Oral Dosage Forms (Table I).
Dissolution proﬁle comparisons, in general, refer to the
comparison of two dissolution proﬁles such as that of
reference and test batches, pre-change batch and post-
change batch, and strengths of product to support a biowaiver
for strengths not used in an in vivo bioequivalence trial.
During method development, there are basic attributes that
the method should have to yield appropriate data for f2
comparisons. These attributes include low variability, an
identiﬁable slope in the percent drug dissolved over time,
minimized artifacts that can bias the shape of these slopes,
and an ability to detect changes in product critical quality
attributes (CQAs). Furthermore, an understanding of the
release mechanism(s) and linkage to clinical outcome are
imperative for obtaining a meaningful and Bclinically
relevant^ dissolution method.
When developing a dissolution method, the variability of
the data should be monitored and minimized as much as
possible. Within any given formulation, high between-unit
variability will negatively impact the discriminatory power of
this test. Variability may be inherent to the dissolution behavior
of the formulations or it may be an artifact of the dissolution
method, e.g., coning, tablet landing and sticking to an off-center
position under the paddle, capsule pellicle formation, spinning
of the dosage unit, and a variety of other clearly noticeable
dissolution anomalies (5). All six dissolution vessels should be
observed to determine if the anomalies are consistent in all six
vessels or only observed in 1 or 2 of the vessels.
A practical consideration has been the implementation
of variability constrains when conducting a proﬁle compari-
son using the f2 metric. The relative standard deviation
(RSD) should be not more than (NMT) 20% at time points
less than or equal to 15 min and the RSD should be NMT
10% for all other points. One could argue that these rules on
variability are really quite generous. However, when earlier
time points are needed for the f2 calculations, this can be a
problem. Five-minute time points are needed when rapid
disintegration is taking place, therefore variability is
expected.
The f2 rules dictate that the number of dosage units
should be 12 of both of the reference and test or post-change
drug products. At least three time points are required, and
only one dissolution value above 85% can be used in the
calculation (2,6–8). The similarity factor, f2 is not needed
when greater than 85% of the labeled amount of drug in the
drug products has been dissolved within 15 min when tested
in 0.1 N HCl, pH 4.5 acetate buffer, and pH 6.8 phosphate
buffer.
One challenge with existing criteria is that the in vivo
release may be multiphasic, thereby limiting the ability of
the f2 metric to predict in vivo product. For example, if
an oral product was developed to be locally acting and is
designed to be intact until at least pH 6.8 or greater
(reaches the distal GI tract) and then a burst of drug
(greater than 80%) is released in 15–30 min after reaching
the site, one could argue that this proﬁle would be similar
to that of an immediate-release product dissolution and
that the f2 rules would be applicable. It might make sense
to set the criteria as >85% dissolved in 60 or 90 min at
pH 6.8 phosphate buffer or higher and zero dissolution
when tested in 0.1 N HCl and pH 4.5 acetate buffer
rather than calculate an f2 value. With this type of release
mechanism, it may be best to employ a risk-based
approach when setting the in vitro release criteria.
However, in vitro release tests tend to be completed
within 60–90 min. This raises the question of whether or
not the existing rules for f2 remain applicable. Given the
signiﬁcant advances in drug delivery technology and
delivery, further discussion is needed around this point.
STATISTICAL APPROACHES WHEN F2 CANNOT
BE APPLIED
When variability exceeds the f2 rules, other statistical
models should be considered. The following is an overview of
two alternative approaches that may be considered, model
independent or model dependent methods (2).
Model Independent Approaches
One such model is the independent multivariate conﬁ-
dence region procedure (Bootstrap approach) method.
Table I. FDA Guidances for f2
Time points Variability Sample units Measurements
Three to four or more RSD NMT 20% for earlier
time point (e. g. 15 min)a
Same dissolution conditions for
both reference and test product
Use mean value of 12 units for each
reference and test product
Same for both reference
(prechange) and test product
RSD NMT 10% for the other
time points
Reference batch should be most
recently manufactured
Only one measurement after 85%
of both products
aThe example is 10 min in the Guidance for Industry, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release
Solid Oral Dosage Forms Based on the a Biopharmaceutics Classiﬁcation System
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Bootstrap allows for the use of f2, not as a point
estimator but as a conﬁdence interval, thus overcoming
concerns encountered when f2 is used solely as a point
estimate. Computation of the bias corrected and acceler-
ated (BCA) conﬁdence intervals is suggested. The boot-
strap method simulates the distribution of f2 values to
determine whether or not two proﬁles exhibit comparable
in vitro behavior. (6,9) This can include the following
steps:
1. Generate N bootstrap samples (e.g., N=1000) by
resampling independently with replacement from
dissolution data for the test and reference
groups.
2. Calculate f2 values from N bootstrap samples.
3. Calculate the bias correction statistic to correct for
the potential skewed distribution of f2 derived
from the bootstrap samples. This can be achieved
by calculating the acceleration statistic (i.e., the
rate of change of the standard error of the
estimate of the sample statistic) by obtaining n
jackknife samples (e.g., n=24) derived from original
dissolution data.
4. Calculate lower and upper bounds of the conﬁ-
dence interval using type 1 error, f2 values of N
bootstrap samples, bias correction, and acceleration
statistics.
To declare similarity between test and reference
dissolution proﬁles, the lower bound of the conﬁdence
interval must equal 50 or more. To illustrate, the
bootstrap method was applied by the FDA when they
evaluated the reformulated 400 mg mesalamine delayed-
release (MDR) (DelzicolTM) against the original 400 mg
mesalamine modiﬁed-release tablets (10). The newly
marketed MDR capsule and discontinued tablet
(Asacol®) formulations have a pH-dependent release
mechanism designed to delay release until the formulation
reaches the distal gastrointestinal (GI) tract (pH~6.5),
thus, increasing the level of exposure to the colon in
patients with ulcerative colitis. The dissolution character-
istics and pharmacokinetics of these MDR capsules and
tablets are highly variable. As part of the reformulation
program to market the capsule formulation, the similarity
of dissolution proﬁles to the original MDR tablet formu-
lation were needed across various pH values to provide
the necessary assurance of comparable product perfor-
mance (10). For modiﬁed-release oral dosage forms such
as DelzicolTM that are developed for targeted local drug
delivery within the GI tract, the dissolution proﬁles must
contain at least three timepoints (11). As stated in the
SUPAC MR 1997 guidance, BAdequate sampling should
be performed, for example, at 1, 2, and 4 h and every two
hours thereafter until either 80% of the drug from the
drug product is released or an asymptote is reached.^ (12)
(Fig. 1).
A multipoint dissolution proﬁle comparison was
generated between the mesalamine capsules and tablets
over a range of pH values (pH 4.5, 6.0, 6.5, 6.8, 7.2, and
7.5). The similarity factors (f2) values were calculated and
provided for each dissolution media. Figure 2 displays the
dissolution proﬁles before and after the formulation
change at pH at 7.2, for which the f2 value was calculated
to be 55.5 by the applicant. The variability (%RSD) in
the dissolution data was very high at the 15- (170.1%), 30-
(80.9%) and 45- (33.4%) min time points. Because of this,
the f2 test could not be used and the FDA applied the
model independent bootstrap approach.
The bootstrap lower conﬁdence interval with a bias
correction was equal to 49.8. The FDA accepted this
value in demonstrating similarity of the two products. The
bootstrap method should not be used to improve an f2
but rather it should be used as a mechanism for dealing
with the issue of data variability. It is noted that there is
an open software available for the bootstrap calculation
(13).
Model Dependent Approaches
The model dependent approach is recommended for
the dissolution data which consist of at least four or more
dissolution data points. The approach includes the selec-
tion of a suitable mathematical function to describe the
dissolution data. Several mathematical models have been
described in the literature to ﬁt dissolution proﬁles
(2,14,15) including Probit, Logistic, Weilbull, Quadric and
Exponential, Hixson-Crowell k, and ﬁrst-order k. The
ultimate choice for the model is made based on the
goodness of ﬁt criteria such as the least residual mean
square error and Akaike Information Criteria. Ideally, an
acceptable ﬁt shows relatively small differences between
the ﬁtted and the observed data, presenting no trends in
residual error, and includes a small number of model
parameters (a model with no more than three parameters
is recommended (2)).
Having a selected mathematic model, additional steps
are needed to accomplish the model-dependent approaches
(2):
1. Deﬁne an appropriate similarity region based on
intra- and inter-batch variances of the ﬁtted
model for test units from the standard approved
batches.
2. Estimate the model parameters by ﬁtting individual
units (12 units) of the reference and the test to the
chosen mathematical function.
3. Calculate the statistical distance between the mean
parameters of the test and reference.
4. Calculate a 90% conﬁdence region around the statis-
tical distance is computed.
5. Compare the limits of the conﬁdence region with pre-
deﬁned similarity region to declare either similarity or
dissimilarity of the proﬁles.
Bootstrap methods generally make no assumptions
about data distribution; hence, they can be a useful approach
when there are too few data to test or verify model
assumptions. Disadvantage of the use of the model-
dependent approach is that there is no single universally
accepted method to evaluate the validity of the statistical
assumptions of the model. Examples of model-dependent
approaches to characterize in vitro dissolution proﬁles are
presented elsewhere (14,15).
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The similarity f2 test should not be used when an approved
in vitro in vivo correlation (IVIVC) model is available for the
drug product. In this case, the IVIVC model should be used to
predict the rate (Cmax) and extent (AUC) of systemic exposure
based on dissolution proﬁle data of the Btest^ and Breference^
products (before and after the speciﬁc proposed CMC change).
Fig. 1. Modiﬁed-release dissolution time points
Fig. 2. Example: bootstrap versus original method for f2 determination results
304 Stevens et al.
REGULATORY APPLICATIONS OF F2
The Application of f2 in QbD
Dissolution and f2 testing can be used to link clinical
performance to critical manufacturing and process attributes
and therefore used to set clinically relevant manufacturing
process controls and product speciﬁcations that provide
assurance of consistent quality product throughout its life
cycle.
Is f2 Applicable to All Dosage Forms?
When the drug availability is spontaneous (e.g., inhala-
tion), or when the drug release rate is preprogrammed (e.g.,
implants), statistical tests of the dissolution proﬁle similarity
may not adequately characterize in vivo product perfor-
mance. In these cases, other test procedures may be necessary
(e.g., aerodynamics, particle size distribution, diffusion cell
systems, dose counter).
Dosage forms where f2 has been shown to be applicable
include the following:
& Simple dosage forms: immediate release
& Oral complex dosage forms: modiﬁed release (DR,
ER) and combination (IR/IR, IR/MR, MR/MR)
products
& Non-oral dosage forms, including transdermal drug
delivery systems and drug-device combination
products
FREQUENTLY ASKED QUESTIONS
1. If dissolution proﬁle is incomplete can f2 be estimated?
& Scenario 1—plateau is not reached: no
& Scenario 2—plateau is reached: yes
2. When is it not necessary to calculate the f2 value?
& The product used in pivotal human study is the same as that
being commercialized
3. Can the f2 test be estimated across studies?
& Yes, in some cases, f2 can be estimated across studies. It is
possible to use f2 when the study materials being compared
are of the same age (shelf-life) and if the same dissolution
method (and detection method) is being used for the
analysis, for example, comparing batches that have been
manufactured after a process change with product batches
that were submitted in an approval. The comparison would
be the initial data from the approval batches with the initial
data from the changed batches. In the case of clinical trial
material being compared to a formulation change prior to
marketing, the dissolution proﬁles can be compared if the
dissolution method and detection methods are the same
and the age of the product when it was tested is the same as
the new product being tested.
4. Can f2 be used to evaluate similarity of in vitro drug release
proﬁles of non-oral drug-device combination products?
& Yes, if the products are evaluated using the same testing
conditions and share identical rate controlling factors for
the in vitro and in vivo drug release.
5. If dissolution is complete in less than 15 min, are there
additional considerations that are needed before
declaring proﬁle comparability?
& May need additional earlier time points (e.g., 5, 10 min).
& May need to change dissolution testing conditions (harsh to
mild).
6. What factors can potentially contribute to variability
in dissolution proﬁles?
& Dissolution method related (as previously discussed).
& Formulation related.
& Analytical method related.
CONCLUSIONS
When planning the statistical method to be applied
for proﬁle comparison, there are several pivotal consid-
erations that need to be integrated into the study design.
Model-dependent or independent approaches should be
considered to conﬁrm prolife similarity. The variability
should be minimized and the release proﬁle should
contain at least three time points to be eligible for the
f2 calculation. When developing a new drug product, it
is prudent to plan for dissolution documentation during
all phases of drug development so that if a change is
needed in formulation, manufacturing process, equip-
ment, or manufacturing site, dissolution proﬁles and f2
data can be used in lieu of the need to conduct PK/
clinical trials.
The f2 test can be invaluable for evaluating the similarity
of the dissolution proﬁles, thereby supporting product
manufacturing and development based upon quality by
design, supporting the product and process throughout the
design space.
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